David Burns

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Cooley advised 3SBio, a leading Chinese biopharmaceutical company, on antitrust aspects of its up to $6 billion+ exclusive licensing agreement with Pfizer for the development, manufacture and commercialization of SSGJ-707, a bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).

Cooley advised Alexandr Wang, Scale AI’s founder, in connection with Scale AI’s significant new investment from Meta Platforms that values the startup at more than $29 billion.

Cooley advised Philochem AG, a wholly owned subsidiary of the Philogen Group (Milan Stock Exchange: PHIL), on its definitive license agreement with RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), granting RayzeBio exclusive worldwide rights to develop, manufacture and commercialize OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer.

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.